Structural analysis of the lipid A isolated from Hafnia alvei 32 and PCM 1192 lipopolysaccharides.
Hafnia alvei, a Gram-negative bacterium, is an opportunistic pathogen associated with mixed hospital infections, bacteremia, septicemia, and respiratory diseases. The majority of clinical symptoms of diseases caused by this bacterium have a lipopolysaccharide (LPS, endotoxin)-related origin. The lipid A structure affects the biological activity of endotoxins predominantly. Thus, the structure of H. alvei lipid A was analyzed for the first time. The major form, asymmetrically hexa-acylated lipid A built of beta-D-GlcpN4P-(1-->6)-alpha-D-GlcpN1P substituted with (R)-14:0(3-OH) at N-2 and O-3, 14:0(3-(R)-O-12:0) at N-2', and 14:0(3-(R)-O-14:0) at O-3', was identified by ESI-MS(n) and MALDI-time-of-flight (TOF) MS. Comparative analysis performed by MS suggested that LPSs of H. alvei 32, PCM 1192, PCM 1206, and PCM 1207 share the identified structure of lipid A. LPSs of H. alvei are yet another example of enterobacterial endotoxins having the Escherichia coli-type structure of lipid A. The presence of hepta-acylated forms of H. alvei lipid A resulted from the addition of palmitate (16:0) substituting 14:0(3-OH) at N-2 of the alpha-GlcpN residue. All the studied strains of H. alvei have an ability to modify their lipid A structure by palmitoylation.
Lukasiewicz
Jolanta
J
L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, PL-53-114 Wroclaw, Poland. czaja@iitd.pan.wroc.pl
Jachymek
Wojciech
W
Niedziela
Tomasz
T
Kenne
Lennart
L
Lugowski
Czeslaw
C
D000215:Acylation; D020611:Hafnia alvei / Q000737:chemistry*; D008050:Lipid A / Q000737:chemistry* / Q000302:isolation & purification*; D009844:Oligosaccharides / Q000737:chemistry; D010100:Oxygen / Q000737:chemistry; D021241:Spectrometry, Mass, Electrospray Ionization; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D008050:Lipid A; D009844:Oligosaccharides; D010100:Oxygen
Avian Pathol. 2004 Apr;33(2):200-4
15276988
J Biol Chem. 1983 Nov 10;258(21):12801-3
6355095
Cell. 1998 Oct 16;95(2):189-98
9790526
Clin Microbiol Rev. 2006 Jan;19(1):12-8
16418520
Eur J Biochem. 1996 May 1;237(3):635-41
8647107
PLoS Pathog. 2006 Jun;2(6):e67
16846256
J Mass Spectrom. 2004 Apr;39(4):378-83
15103651
Carbohydr Res. 1996 Oct 4;292:117-28
8870241
Carbohydr Res. 1979 Dec;77:10-7
519653
J Bacteriol. 2008 Aug;190(15):5256-64
18515419
Eur J Biochem. 1999 Nov;266(1):53-61
10542050
Eur J Biochem. 1996 Apr 1;237(1):272-8
8620884
J Appl Microbiol. 2008 Nov;105(5):1614-22
18795976
J Mass Spectrom. 1996 Feb;31(2):138-49
8799267
J Lipid Res. 2002 Dec;43(12):2188-95
12454282
Science. 1997 Apr 11;276(5310):250-3
9092473
Carbohydr Res. 1997 Mar 5;298(3):219-27
9090816
Eur J Biochem. 1997 May 1;245(3):668-75
9183004
Acta Biochim Pol. 1995;42(1):51-4
7653161
Eur J Biochem. 1997 Mar 1;244(2):580-6
9119027
Mol Microbiol. 2005 Aug;57(4):900-12
16091033
Eur J Immunol. 1986 Oct;16(10):1263-7
3490388
FEMS Immunol Med Microbiol. 1999 May;24(1):63-71
10340714
Biochemistry. 2006 Sep 5;45(35):10434-47
16939196
Carbohydr Res. 1995 Apr 3;269(1):125-38
7539717
FEMS Immunol Med Microbiol. 1995 Jan;10(2):119-24
7719279
J Lipid Res. 2007 Nov;48(11):2419-27
17703058
J Bacteriol. 2009 Jan;191(2):533-44
19011031
Mol Microbiol. 2005 Jan;55(2):425-40
15659161
J Mass Spectrom. 2004 May;39(5):514-25
15170747
Anal Biochem. 2002 Aug 1;307(1):131-7
12137789